Biomarkers for intervertebral disc and associated back pain: From diagnosis to disease prognosis and personalized treatment

Biomarkers are commonly recognized as objective indicators of a medical state or clinical outcome and have been widely used as clinical and diagnostic tools and surrogate endpoints in many pathological conditions. In the context of intervertebral disc (IVD) and associated back pain, also known as degenerative disc disease (DDD), the use of biomarkers has been poorly explored. DDD is currently diagnosed using imaging techniques and subjective pain scales, limiting an objective association between DDD and pain levels, as well as an evaluation of disease progression. There is a need for objective and reliable measurements for DDD, pain and pathology progression. DDD predictors could also help clinicians in deciding on the optimal treatment for distinct patient groups. This review addresses the current candidate biomarkers in DDD, including imaging, genetic, metabolite and protein-based parameters, both at the tissue and systemic levels, that may become a major advance in the diagnosis and prognosis of the disease, as well as in the management of therapeutic approaches to DDD. Candidate biomarkers of IVD disorders and associated pain identified through imaging techniques, gene expression, protein analysis, in the IVD tissue or systemically. (Figure created with under the Biorender agreement number: MN259AP2SA, and partly adapted from: Mallio, C.A.; Vadala, G.; Russo, F.; Bernetti, C.; Ambrosio, L.; Zobel, B.B.; Quattrocchi, C.C.; Papalia, R.; Denaro, V. Novel magnetic resonance imaging tools for the diagnosis of degenerative disc disease: A narrative review. Diagnostics 2022;12:420).image